Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia (Q33872754)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

author name string

Judith E Karp

1

1 reference

Europe PubMed Central

29 July 2017

Amanda Blackford

2

1 reference

Europe PubMed Central

29 July 2017

B Douglas Smith

3

1 reference

Europe PubMed Central

29 July 2017

Katrina Alino

4

1 reference

Europe PubMed Central

29 July 2017

Amy Hatfield Seung

5

1 reference

Europe PubMed Central

29 July 2017

Javier Bolaños-Meade

6

1 reference

Europe PubMed Central

29 July 2017

Jacqueline M Greer

7

1 reference

Europe PubMed Central

29 July 2017

Hetty E Carraway

8

1 reference

Europe PubMed Central

29 July 2017

Steven D Gore

9

1 reference

Europe PubMed Central

29 July 2017

Richard J Jones

10

1 reference

Europe PubMed Central

29 July 2017

Mark J Levis

11

1 reference

Europe PubMed Central

29 July 2017

Michael A McDevitt

12

1 reference

Europe PubMed Central

29 July 2017

L Austin Doyle

13

1 reference

Europe PubMed Central

29 July 2017

John J Wright

14

1 reference

Europe PubMed Central

29 July 2017

publication date

4 December 2009

1 reference

Europe PubMed Central

29 July 2017

Leukemia Research

1 reference

Europe PubMed Central

29 July 2017

34

1 reference

Europe PubMed Central

29 July 2017

7

1 reference

Europe PubMed Central

29 July 2017

877-882

1 reference

Europe PubMed Central

29 July 2017

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Acute myeloid leukemia and myelodysplastic syndromes in older patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Age and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

Hypokalaemia in Acute Myeloid Leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

5 July 2018

End points to establish the efficacy of new agents in the treatment of acute leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875369

29 October 2018

Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19962759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The acute monocytic leukemias: multidisciplinary studies in 45 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19962759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A two-step timed sequential treatment for acute myelocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19962759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19962759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19962759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.LEUKRES.2009.11.007

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33872754&oldid=1645039756"